Art Medical Ltd.

Art Medical Ltd. is a healthcare technology company specializing in nutrition management solutions for critical care environments, aimed at improving patient outcomes in hospitals. Founded in 2009 in Netanya, Israel, Art Medical Ltd. focuses on providing innovative solutions for healthcare challenges.

The company's approach has remained consistent, with no notable pivots or subsidiary structures. The firm was established by a team of experts in the medical field. In June 2017, Art Medical Ltd. raised USD 20 mn in venture funding led by Advanced Medical Technologies Ltd.

, marking its most recent investment round. The company has successfully completed one deal to date. Art Medical Ltd. 's core offering is the smART+ platform, a comprehensive nutrition management solution designed specifically for critical care environments.

This innovative platform integrates sensor-based tools, proprietary software, and algorithms to tackle critical issues such as malnutrition and aspiration pneumonia in ICU patients. The smART+ system provides personalized nutrition therapy, thereby reducing the risks associated with feeding practices in critically ill patients. Targeted primarily at hospitals and healthcare facilities in the United States, the platform addresses the needs of an estimated one million patients facing complications from ventilator-associated events annually. Art Medical Ltd.

generates revenue primarily through direct sales of its smART+ platform to healthcare providers, hospitals, and critical care facilities. The business model includes both direct transactions and potential partnerships with healthcare systems that may involve subscription services for ongoing access to their software and updates. Pricing plans are tailored for institutional buyers, reflecting the value of improved patient outcomes and reduced healthcare costs. Contracts often encompass the purchase of the smART+ system along with ancillary sensor-based tools that enhance its functionality.

Art Medical Ltd. plans to leverage recent funding from the USD 20 mn raised in June 2017 to enhance the smART+ platform and develop new products aimed at improving patient care. The company is exploring expansion into additional markets within Europe and Asia by 2025, which will involve strategic partnerships with regional healthcare providers. These initiatives are part of the company’s broader strategy to increase its footprint in the global healthcare market and to further its mission of addressing malnutrition in critical care settings.